Abstract
Matrix metalloproteinases (MMPs) are zinc enzymes responsible for the degradation of the extracellular matrix. With this function, MMPs are involved in many physiological processes, but also in many pathological states. MMP-13 is implicated in the degradation of type II collagen, the main structural protein of articular cartilage, contributing to the development of osteoarthritis and inflammatory diseases. In the last years, a new generation of potent and selective MMP inhibitors (MMPIs) has been identified and classified as non-zinc-binding inhibitors (NZBIs). Several MMP-13 NZBIs have been developed and crystallographically determined in complex with the enzyme. Here, we provide a detailed review of the current knowledge about this class of MMP-13 inhibitors and, by using computational procedures, we highlight the molecular determinants that are needed for the binding process. In particular, FLAP, a program based on GRID molecular interaction fields, was used to analyze the ligand-protein interactions: molecular shape and hydrogen bond acceptor groups strongly influence the binding according to the ligand-based modeling, while the aromatic interactions are better identified by the structure-based study. The complementary results can be combined in a high performance model, showing the effectiveness of molecular interaction field based approaches to search for novel MMP-13 NZBIs.
Keywords: Drug design, Binding pocket, GRID, MMP-13, Molecular modeling, Molecular similarity, Non-zinc-binding inhibitors.
Current Topics in Medicinal Chemistry
Title:Non-Zinc-Binding Inhibitors of MMP-13: GRID-Based Approaches to Rationalize the Binding Process
Volume: 16 Issue: 4
Author(s): Antonella Di Pizio, Mariangela Agamennone and Paolo Tortorella
Affiliation:
Keywords: Drug design, Binding pocket, GRID, MMP-13, Molecular modeling, Molecular similarity, Non-zinc-binding inhibitors.
Abstract: Matrix metalloproteinases (MMPs) are zinc enzymes responsible for the degradation of the extracellular matrix. With this function, MMPs are involved in many physiological processes, but also in many pathological states. MMP-13 is implicated in the degradation of type II collagen, the main structural protein of articular cartilage, contributing to the development of osteoarthritis and inflammatory diseases. In the last years, a new generation of potent and selective MMP inhibitors (MMPIs) has been identified and classified as non-zinc-binding inhibitors (NZBIs). Several MMP-13 NZBIs have been developed and crystallographically determined in complex with the enzyme. Here, we provide a detailed review of the current knowledge about this class of MMP-13 inhibitors and, by using computational procedures, we highlight the molecular determinants that are needed for the binding process. In particular, FLAP, a program based on GRID molecular interaction fields, was used to analyze the ligand-protein interactions: molecular shape and hydrogen bond acceptor groups strongly influence the binding according to the ligand-based modeling, while the aromatic interactions are better identified by the structure-based study. The complementary results can be combined in a high performance model, showing the effectiveness of molecular interaction field based approaches to search for novel MMP-13 NZBIs.
Export Options
About this article
Cite this article as:
Pizio Di Antonella, Agamennone Mariangela and Tortorella Paolo, Non-Zinc-Binding Inhibitors of MMP-13: GRID-Based Approaches to Rationalize the Binding Process, Current Topics in Medicinal Chemistry 2016; 16 (4) . https://dx.doi.org/10.2174/1568026615666150813150631
DOI https://dx.doi.org/10.2174/1568026615666150813150631 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Adaptogens—History and Future Perspectives
Adaptogens are pharmacologically active compounds or plant extracts that are associated with the ability to enhance the body’s stability against stress. The intake of adaptogens is associated not only with a better ability to adapt to stress and maintain or normalise metabolic functions but also with better mental and physical ...read more
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Challenges, Consequences and Possible Treatments of Anticancer Drug Discovery ll
The use of several compounds has been the subject of increasing interest in phytochemistry, biochemistry, and other fields of research at the chemistry-biology-ecosystems interface. In spite of the continued search for new anticancer drugs, cancer remains a leading cause of death. Cancer mortalities are expected to increase to 12.9 million, ...read more
Chronic Kidney Disease
The scope of the special thematic issue includes but not limited to the mechanism of chronic kidney disease (CKD), the treatment of renal fibrosis and early diagnosis of CKD and so on. We also welcome manuscripts from other scientific research area with respect to internal medicine. Cell death has been ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Is there Evidence to Support the Use of Direct Factor Xa Inhibitors in Coronary Artery Disease?
Reviews on Recent Clinical Trials Exploring the Mechanism of Si-miao-yong-an Decoction in the Treatment of Coronary Heart Disease based on Network Pharmacology and Experimental Verification
Combinatorial Chemistry & High Throughput Screening Large Artery Stiffness and Antihypertensive Agents
Current Pharmaceutical Design Antenatal Maternal Antidepressants Drugs Affect S100B Concentrations in Fetal-Maternal Biological Fluids
CNS & Neurological Disorders - Drug Targets HHT: A Rare Disease with A Broad Spectrum of Clinical Aspects
Current Pharmaceutical Design Clinical and Imaging Findings in the Alveolar Echinococcosis
Current Medical Imaging Mechanisms and Characteristics of Sulfonylureas and Glinides
Current Topics in Medicinal Chemistry Does It Make Sense that Diabetes is Reciprocally Associated with Periodontal Disease?
Endocrine, Metabolic & Immune Disorders - Drug Targets Novel Insights into Vascular Repair Mechanisms
Current Pharmaceutical Design Brain Peptides for the Treatment of Neuropsychiatric Disorders
Current Pharmaceutical Design Targeted Temperature Management in Spontaneous Intracerebral Hemorrhage: A Systematic Review
Current Drug Targets Non-Invasive Assessment of Atherosclerosis Risk
Current Drug Targets - Cardiovascular & Hematological Disorders A Comprehensive Review on Targeted Cancer Therapy: New Face of Treatment Approach
Current Pharmaceutical Design The Underestimated Role of Mechanical Stimuli in Brain Diseases and the Relate d In Vitro Models
Current Pharmaceutical Design ESVS Guidelines: Section A - Prevention in Patients with Carotid Stenosis
Current Vascular Pharmacology Determinants of Longevity: Genetics, Biomarkers and Therapeutic Approaches
Current Pharmaceutical Design Inflammation as a Therapeutic Target for Various Deadly Disorders: A Review
Current Drug Targets Dual Modulation of Vascular Function by Perivascular Adipose Tissue and Its Potential Correlation with Adiposity/Lipoatrophy-Related Vascular Dysfunction
Current Pharmaceutical Design Knowing is Half the Battle: Targeting Virulence Factors of Group A Streptococcus for Vaccine and Therapeutics
Current Drug Targets Prognostic Value of Coronary Artery Calcification
Vascular Disease Prevention (Discontinued)